Morgan Stanley Maintains Stevanato Group(STVN.US) With Hold Rating, Maintains Target Price $22
Morgan Stanley Maintains Stevanato Group(STVN.US) With Hold Rating, Maintains Target Price $22
Morgan Stanley Maintains Stevanato Group(STVN.US) With Hold Rating, Maintains Target Price $22
Morgan Stanley Reaffirms Their Hold Rating on Stevanato Group (STVN)
Morgan Stanley Maintains Stevanato Group(STVN.US) With Hold Rating, Maintains Target Price $22
Morgan Stanley Maintains Stevanato Group(STVN.US) With Hold Rating, Maintains Target Price $22
Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN), Pharvaris (PHVS) and Stevanato Group (STVN)
Morgan Stanley Maintains Stevanato Group(STVN.US) With Hold Rating, Maintains Target Price $22
Morgan Stanley Remains a Hold on Stevanato Group (STVN)
Stevanato Gr Analyst Ratings
UBS Adjusts Price Target on Stevanato to $23 From $24, Maintains Neutral Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Organon (OGN), Stevanato Group (STVN) and DaVita (DVA)
Bank of America Securities Sticks to Their Buy Rating for Stevanato Group (STVN)
Stevanato Gr Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Stevanato Gr, Lowers Price Target to $22
Morgan Stanley Lowers Price Target on Stevanato Group to $22 From $26, Keeps Equalweight Rating
Stevanato Group (STVN) Gets a Hold From Morgan Stanley
Jefferies Keeps Their Hold Rating on Stevanato Group (STVN)
Morgan Stanley Lowers Price Target on Stevanato Group to $26 From $30, Keeps Equalweight Rating
Bank of America Securities Reaffirms Their Buy Rating on Stevanato Group (STVN)